Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer

4 941

Cited 0 times in

Cited 6 times in

Authors: Seungtaek Lim ; Soohyeon Lee ; Jungwoo Han ; Byeong-Woo Park ; SeungIl Kim ; Seho Park ; Joo-Hang Kim ; Hye Jin Choi ; Joohyuk Sohn

MeSH: Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use* ; Aromatase Inhibitors/adverse effects ; Aromatase Inhibitors/therapeutic use* ; Breast Neoplasms/chemistry ; Breast Neoplasms/drug therapy* ; Breast Neoplasms/pathology ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Maintenance Chemotherapy* ; Middle Aged ; Neoplasm Metastasis ; Palliative Care* ; Receptors, Estrogen/analysis ; Receptors, Progesterone/analysis ; Retrospective Studies ; Selective Estrogen Receptor Modulators/adverse effects ; Selective Estrogen Receptor Modulators/therapeutic use*

Keywords: Breast cancer ; ER ; Hormone therapy ; MBC ; MHT ; MPA ; Maintenance ; OS ; PFS ; PR ; RECIST ; estrogen receptor ; maintenance hormone therapy ; medroxyprogesteron acetate ; metastatic breast cancer ; overall survival ; progesterone receptor ; progression free survival ; response evaluation criteria in solid tumors

Abstract: Objective
We investigated the efficacy of maintenance hormone therapy (MHT), which was given to hormone positive metastatic breast cancer (MBC) patients in non-progression status to the previous chemotherapy.

Methods
This study retrospectively analyzed 76 MBC patients who had been treated with MHT from 2006 to 2010 at a single institute.

Results
For the 76 patients reviewed, the median progression free survival (PFS) to MHT was 14.4 months (95% CI, 11.6–17.3). Prolonged PFS was associated with less previous palliative chemotherapy, fewer metastatic sites, and the absence of visceral metastasis in univariate analysis. Multivariate analysis showed that only the number of previous palliative chemotherapy (HR 1.73, 95% CI, 1.00–2.98; P = 0.04) remained as a significant variable. MHT was generally well tolerated.

Full Text: http://www.sciencedirect.com/science/article/pii/S0960977613002476

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

Yonsei Authors: Kim, Seung Il(김승일)
Kim, Joo Hang(김주항)
Park, Byeong Woo(박병우) https://orcid.org/0000-0003-1353-2607
Park, Se Ho(박세호) https://orcid.org/0000-0001-8089-2755
Sohn, Joo Hyuk(손주혁) https://orcid.org/0000-0002-2303-2764
Lee, Soo Hyeon(이수현)
Lim, Seung Taek(임승택)
Choi, Hye Jin(최혜진) https://orcid.org/0000-0001-5917-1400
Han, Jung Woo(한정우) https://orcid.org/0000-0001-8936-1205

Show full item record Find it @ YMLIB

YUHSpace: Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer